| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Abexinostat (formerly PCI-24781; CRA-024781) is a novel, potent and hydroxamic acid-based pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. It shows moderate potency against HDAC2/3/6/10, >40-fold selectivity over HDAC8, and primarily inhibits HDAC1 with a Ki of 7 nM. Both in vivo and in vitro antitumor efficaciousness are strong points of this substance. Phase II clinical trials are investigating abexinostat (PCI24781; CRA024781) for B-cell lymphoma.
| Targets |
HDAC1 ( Ki = 7 nM ); HDAC3/SMRT ( Ki = 8.2 nM ); HDAC6 ( Ki = 17 nM ); HDAC2 ( Ki = 19 nM ); HDAC10 ( Ki = 24 nM ); HDAC8 ( Ki = 280 nM ); MBLAC2 ( Ki < 10 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
A trypsin-coupled assay that runs continuously is used to measure HDAC activity. Measurements in a reaction volume of 100 μL using 96-well assay plates are performed for inhibitor characterization. The HDAC protein is combined with PCI-24781 at different concentrations for each isozyme and incubated for 15 minutes. The reaction buffer is 50 mM HEPES, 100 mM KCl, 0.001% Tween 20, 5% DMSO (pH 7.4), supplemented with bovine serum albumin at concentrations of 0% (HDAC1), 0.01% (HDAC2, 3, 8, and 10), or 0.05% (HDAC6). The reaction is started by adding acetyl-Gly-Ala-(N-acetyl-Lys)-AMC at a final concentration of 25 μM (HDAC1, 3, and 6), 50 μM (HDAC2 and 10), or 100 μM (HDAC8). Trypsin is added to a final concentration of 50 nM. In duplicates of eight, negative control reactions are carried out without PCI-24781. A fluorescence plate reader is used to track reactions. The fluorescence is measured over a 30-minute period with an excitation wavelength of 355 nm and a detection wavelength of 460 nm, following a 30-minute lag time. Reaction rate is calculated using the fluorescence increase over time. The program BatchKi is used to obtain inhibition constants Ki(app).
|
|
| Cell Assay |
Following at least two doubling times of culture for ten tumor cell lines and HUVEC, growth is assessed using an Alamar blue fluorometric cell proliferation assay to determine the end of compound exposure. The compound is assayed using half-log intervals ranging from 0.0015 to 10 μmol/L in triplicate wells in 96-well plates at nine concentrations. Each well has a final DMSO concentration of 0.15%. A four-parameter logistic equation is used to estimate the concentration needed to inhibit cell growth by 50% and 95% confidence intervals through nonlinear regression[1].
|
|
| Animal Protocol |
|
|
| References |
|
| Molecular Formula |
C21H23N3O5
|
|
|---|---|---|
| Molecular Weight |
397.42
|
|
| Exact Mass |
397.16
|
|
| Elemental Analysis |
C, 63.46; H, 5.83; N, 10.57; O, 20.13
|
|
| CAS # |
783355-60-2
|
|
| Related CAS # |
|
|
| Appearance |
White to off-white solid powder
|
|
| SMILES |
CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
|
|
| InChi Key |
MAUCONCHVWBMHK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
|
|
| Chemical Name |
3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide
|
|
| Synonyms |
CRA024781; PCI24781; CRA 024781; PCI-24781; CRA024781; PCI 24781; CRA-024781
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5162 mL | 12.5811 mL | 25.1623 mL | |
| 5 mM | 0.5032 mL | 2.5162 mL | 5.0325 mL | |
| 10 mM | 0.2516 mL | 1.2581 mL | 2.5162 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03939182 | Active Recruiting |
Drug: Abexinostat Drug: Ibrutinib |
Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma |
Memorial Sloan Kettering Cancer Center |
May 29, 2019 | Phase 1 |
| NCT03600441 | Active Recruiting |
Drug: Abexinostat | Follicular Lymphoma | Xynomic Pharmaceuticals, Inc. | August 27, 2018 | Phase 2 |
| NCT03590054 | Active Recruiting |
Drug: Abexinostat Biological: Pembrolizumab |
Locally Advanced Melanoma Metastatic Melanoma |
Rahul Aggarwal | August 20, 2018 | Phase 1 |
| NCT03934567 | Recruiting | Drug: Abexinostat | Lymphoma, Follicular | Xynomic Pharmaceuticals, Inc. | April 22, 2020 | Phase 2 |
| NCT03936153 | Recruiting | Drug: abexinostat | Diffuse Large B-cell Lymphoma (DLBCL) |
Xynomic Pharmaceuticals, Inc. | January 20, 2020 | Phase 2 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
